Citation Impact
Citing Papers
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs
2008
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
Cancer statistics, 2022
2022 Standout
Cancer statistics, 2023
2023 Standout
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
Identification of a Small Interface between the Methyltransferase and RNA Polymerase of NS5 that is Essential for Zika Virus Replication
2018 StandoutNobel
Cancer statistics, 2020
2020 Standout
Cancer statistics, 2019
2019 Standout
Cancer Statistics, 2021
2021 Standout
Engineering precision nanoparticles for drug delivery
2020 Standout
Cancer drug delivery in the nano era: An overview and perspectives
2017
Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents
2015
Dasatinib
2009
A view on drug resistance in cancer
2019 StandoutNature
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
2014
The Ikaros gene family: Transcriptional regulators of hematopoiesis and immunity
2011
New treatment for acute myelogenous leukemia
2014
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
2013 StandoutNobel
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Delivery materials for siRNA therapeutics
2013 Standout
The Human Transcription Factors
2018 Standout
The changing landscape of atherosclerosis
2021 StandoutNature
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism
2008
Angiogenesis: an organizing principle for drug discovery?
2007 Standout
Non-viral vectors for gene-based therapy
2014 Standout
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
2010
Sickle-cell disease
2010 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
2011 Standout
Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies
2009
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Applying the discovery of the Philadelphia chromosome
2007
Flying under the radar: the new wave of BCR–ABL inhibitors
2007
Cancer nanomedicine: from targeted delivery to combination therapy
2015
Transcription factor Ikzf1 associates with Foxp3 to repress gene expression in Treg cells and limit autoimmunity and anti-tumor immunity
2024 StandoutNobel
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
2015
Clonal Hematopoiesis
2019
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Cutaneous γδ T-cell Lymphomas
2012
Modes of resistance to anti-angiogenic therapy
2008 Standout
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
2013
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
2009 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Tumor Angiogenesis
2008 Standout
Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily
2009
The cancer genome
2009 StandoutNature
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
2017 StandoutNature
Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors
2015 StandoutNobel
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Nanoparticles in the clinic
2016
Nanoparticle Delivery of Cancer Drugs
2011
Photoexpulsion of Surface-Grafted Ruthenium Complexes and Subsequent Release of Cytotoxic Cargos to Cancer Cells from Mesoporous Silica Nanoparticles
2013 StandoutNobel
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation
2007
Acute Myeloid Leukemia
2015 Standout
Nanoparticles in the clinic: An update
2019
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings
2016
Nanochemistry and Nanomedicine for Nanoparticle-based Diagnostics and Therapy
2016
A circadian gene expression atlas in mammals: Implications for biology and medicine
2014 Standout
Toward the potential cure of leukemias in the next decade
2018
Cancer treatment and survivorship statistics, 2016
2016 Standout
Cancer statistics, 2016
2016 Standout
Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
2015 Standout
Cancer statistics, 2015
2015 Standout
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
2008
Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum
2011 StandoutScience
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials
2016
Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines
2017
Effects of Poverty and Race on Outcomes in Acute Myeloid Leukemia
2010
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Multiple Myeloma
2011 Standout
Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines
2023 StandoutNobel
Translation of the Philadelphia chromosome into therapy for CML
2008
Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology
2014
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Therapy for myeloproliferative neoplasms: when, which agent, and how?
2014
Clinical Translation of Nanomedicine
2015
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
2014
Treatments for chronic myeloid leukemia: a qualitative systematic review
2012
Works of Ellen K. Ritchie being referenced
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
2017
Incidence rates of acute promyelocytic leukemia among Hispanics, blacks, Asians, and non-Hispanic whites in the United States
2006
Lethal T- and NK-cell lymphomas mimicking granulomatous panniculitidies: a clinicopathologic study of three cases
2011
Ikaros increases normal apoptosis in adult erythroid cells
2005
A Phase I Study of CPX-351 in Combination with Busulfan and Fludarabine Conditioning and Allogeneic Stem Cell Transplantation in Adult Patients with Refractory Acute Leukemia
2013
Incidence rates of the major leukemia subtypes among U.S. Hispanics, Blacks, and non-Hispanic Whites
2006
Somatic mutations precede acute myeloid leukemia years before diagnosis
2018
Mechanisms of Resistance to Imatinib in CML Patients: A Paradigm for the Advantages and Pitfalls of Molecularly Targeted Therapy
2006
Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.
2016
First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
2011
Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML
2011
Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results
2014
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
2006
A Phase 2 Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Naïve to 5-Azacitadine: A Preliminary Analysis of Phase 2a
2015
Phase 2B Randomized Study of CPX-351 Vs. Cytarabine (CYT) + Daunorubicin (DNR) (7+3 Regimen) In Newly Diagnosed AML Patients Aged 60–75
2010